Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protein C system proteins and anticoagulant effects of rivaroxaban and dabigatran in nonvalvular atrial fibrillation
ChiCTR2000033145Phase 4Not yet recruiting
- Sponsor
- Shanghai Fifth People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban and dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Shanghai Fifth People's Hospital. Primary endpoints: Incidence of bleeding and Incidence of thrombosis. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
rivaroxabandabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2000033145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033145.